2nd Kloster Seeon Meeting on BACE Proteases in Health and Disease

关于 BACE 蛋白酶在健康和疾病中的作用的第二届 Kloster Seeon 会议

• 批准号: 9195559
• 负责人: ROBERT J VASSAR
• 金额: $ 3.4万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-07-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9195559
• 关键词: Academia; Advanced Development; Adverse effects; Air; Alzheimer disease prevention; Alzheimer' s Disease; Amyloid beta-Protein; Amyloid beta-Protein Precursor; Animal Model; Area; Aspartic Endopeptidases; Award; Behavior; Biochemical; Biological; Brain; Case Study; Cells; Cerebrum; Cleaved cell; Clinical; Clinical Trials; Communities; Complex; Development; Disease; Disease Progression; Enzymes; Fostering; Funding; Genetic; Germany; Goals; Health; Human; Industry; International; Internet; Journals; Knockout Mice; Knowledge; Laboratories; Location; Mutation; Nervous System Physiology; Neurites; Neurosciences; Paper; Pathogenesis; Peptide Hydrolases; Pharmaceutical Preparations; Physiological; Postdoctoral Fellow; Process; Production; Publications; Publishing; Reading; Regulation; Reporter; Reporting; Research; Research Personnel; Retinal; Risk; Role; Safety; Science; Scientist; Senile Plaques; Senior Scientist; Site; Staging; Students; Therapeutic; Toxic effect; Training; Travel; United States National Institutes of Health; Universities; Writing; abeta accumulation; abstracting; amyloid peptide; base; beta secretase; beta-site APP cleaving enzyme 1; cost; drug development; experience; graduate student; improved; inhibitor/antagonist; lectures; meetings; novel; peptide A; posters; prevent; professional atmosphere; programs; research and development; secretase; success; symposium; therapeutic target; transmission process; web site

Project Summary Compelling genetic, biochemical, cell biological, animal model, and human studies suggest that cerebral accumulation of the -amyloid peptide (A) has a critical early role in Alzheimer's disease (AD) pathogenesis. The -secretase enzyme BACE1 is the rate-limiting enzyme for A production. Thus, BACE1 is a prime therapeutic target for the treatment or prevention of AD. Several BACE1 inhibitor drugs for AD are in clinical trials, but the safety and efficacy of these agents are unknown. The BACE proteases field comprises very active and diverse areas of research that have high impact on therapeutic approaches to treat and prevent AD. Here, I propose the 2nd Kloster Seeon Meeting on BACE Proteases in Health and Disease, September 25-27, 2016, in Bavaria, Germany, which has the following objectives: 1) disseminate the latest information on BACE proteases research and catalyze discussion among scientists in academia and industry, 2) promote the training of young scientists, and 3) publish a state-of-the-art review of BACE research to help advance the field and facilitate the development of safe and effective BACE inhibitor drugs for AD. The Scientific Program consists of: 1) a Keynote Lecture by Dr. Kari Stefansson (DeCode Genetics), who recently discovered a mutation in APP that protects against AD by reducing BACE1 cleavage, thus providing proof of concept for therapeutic BACE1 inhibition, 2) two full days of sessions comprising 25-minute talks from 24 leading experts in the BACE proteases field, 3) a session of 2-minute flash talks given by 10 selected graduate students and post-doctoral researchers to introduce their posters, 4) poster sessions on each of two evenings that will enhance the training experience of students and post-docs, 5) a panel discussion between academic and industry scientists on the current state of BACE research and drug development, 6) a conclusion and summary session to remark on the meeting and discuss the direction forward for the field. This meeting is co-organized by Drs. Stefan Lichtenthaler (Technical University Munich) and Robert Vassar (Northwestern University), two leading scientists in the BACE proteases field. The 1st Kloster Seeon Meeting on BACE Proteases in Health and Disease was held at the same location on October 6-8, 2013, and was objectively successful at disseminating the latest BACE research and catalyzing discussion among BACE scientists. Three years have passed, and significant advances in BACE research have been made, including new clinical trials, discoveries of novel BACE1 substrates and functions, different mechanisms of BACE regulation in health and dysregulation in AD, and identification of new proteolytic activities. Given these new advances, the 2nd Kloster Seeon Meeting on BACE Proteases in Health and Disease is timely and important for dissemination of the latest information in the field. Additionally, no other scientific meeting or conference focuses exclusively on BACE proteases research, making this meeting a unique scientific forum that will contribute significantly to the advancement of the AD research and drug development fields.

项目摘要 引人入胜的遗传，生化，细胞生物学，动物模型和人类研究表明脑 淀粉样肽（A）的积累在阿尔茨海默氏病（AD）发病机理中具有至关重要的早期作用。 -分泌酶BACE1是A产生的速率限制酶。那是Bace1是素数 治疗或预防AD的治疗靶标。 AD的几种BACE1抑制剂药物正在临床中 试验，但是这些试剂的安全性和效率尚不清楚。贝斯蛋白酶领域非常包含 对治疗和预防AD的治疗方法具有很大影响的活跃研究领域。 在这里，我提出了第二届克洛斯特·塞翁（Kloster Seeon 2016年，在德国巴伐利亚州，有以下对象：1）传播有关贝斯的最新信息 蛋白酶的研究和催化学术界和工业的科学家之间的讨论，2）促进 对年轻科学家的培训，以及3）发表对尼斯班赛研究的最先进评论，以帮助促进该领域 并促进为AD开发安全有效的BACE抑制剂药物。科学计划 包括：1）Kari Stefansson博士（Decode Genetics）的主题演讲，他最近发现了一个 通过减少Bace1裂解来防止AD的应用中的突变，从而为概念证明 治疗性BACE1抑制作用，2）整整两天的会议完成了24个领先专家的25分钟会谈 在贝斯蛋白酶领域，3）一会儿由10名选定的研究生进行了2分钟的Flash会谈和 博士后研究人员介绍他们的海报，4）在两个晚上的每个晚上的海报会议 增强学生和毕业后的培训经验，5）学术和学术之间的小组讨论 行业科学家关于当前的贝斯研究和药物开发状况，6）结论和摘要 会议会议上会议，并讨论该领域的方向。这次会议是共同组织的 由Drs。 Stefan Lichtenthaler（慕尼黑技术大学）和罗伯特·瓦萨（Robert Vassar）（西北大学），两个 贝斯蛋白酶领域的主要科学家。第一次克洛斯特·塞翁（Kloster Seeon 疾病于2013年10月6日至8日在同一地点举行，客观地取得了成功 传播最新的裁缝研究和催化尼斯科学家之间的讨论。三年有 通过，包括新的临床试验，包括新的临床试验，已经取得了重大进展 新型BACE1底物和功能，健康和健康的不同机制 AD失调以及新蛋白水解活性的识别。鉴于这些新进展，第二克洛斯特 Seeon关于健康和疾病中关于贝斯蛋白酶的会议对于传播的及时而重要 该领域的最新信息。此外，没有其他科学会议或会议专门针对 Bace蛋白酶研究，使这次会议成为一个独特的科学论坛，将对 广告研究和药物开发领域的进步。